This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Auxilium Pharmaceuticals, Inc. Announces IMPRESS Trials Of XIALFEX® In Peyronie's Disease Were Published Online In The Journal Of Urology

Secondary Endpoint Results in IMPRESS I:

  • Improvement from baseline in percentage of global responders and the percentage of composite responders (Intent to Treat analysis) showed statistical significance vs. placebo.
  • Improvement from baseline in the PDQ psychological and physical symptoms and IIEF overall satisfaction, showed trends toward improvement vs. placebo. 

Secondary Endpoint Results in IMPRESS II:
  • Improvement from baseline in percentage of global responders showed statistical significance vs. placebo.
  • Improvement from baseline in PDQ psychological and physical symptoms, IIEF overall satisfaction, percentage of composite responders (Intent to Treat analysis), plaque consistency, and penile length showed trends toward improvement vs. placebo.

A post-hoc meta-analysis of both identical IMPRESS studies' co-primary and secondary endpoints is also presented in the manuscript as each IMPRESS study was not individually powered to meet statistical significance for the secondary endpoints.  The meta-analysis was performed to increase the statistical power for evaluation of those secondary endpoints.  In the meta-analysis, the algorithm for calculating p-values for the co-primary and first family of secondary endpoints was essentially the same as that observed in the two individual studies.

Post-hoc Meta-Analysis – Combination of Identical IMPRESS I and II Studies:
  • Co-primary endpoints maintain statistical significance.
  • The following secondary endpoints met statistical significance, compared to placebo, based on the multiple comparison algorithm within the meta-analysis:
    •  Percentage of global responders
    • Improvement in Peyronie's disease physical and psychological symptom domain
    • Improvement in IIEF overall satisfaction domain
    • Percentage of composite responders (ITT analysis)
    • Improvement in penile plaque consistency
  •  Improvement in penile length and penile pain were not statistically different from placebo.

"The clinical outcomes demonstrated by XIAFLEX in the IMPRESS trials offer great hope and optimism for patients suffering from Peyronie's disease and suggest patients may be successfully treated non-surgically,"  said Martin K. Gelbard, MD, IMPRESS investigator and clinical faculty member of UCLA School of Medicine, Department of Urology. "Currently, urologists have no clinically proven treatment for Peyronie's disease other than surgical intervention, which often is performed as a last resort due to the potential for complications, including decreased penile length or erectile dysfunction.  The potential ability, if FDA approved, to offer an effective in-office medical therapy in XIAFLEX would represent a significant evolution in the standard of care for physicians who treat Peyronie's disease."

Adverse EventsThe most common adverse events reported in the double-blind, placebo-controlled IMPRESS phase III trials were hematoma, pain and swelling at the treatment site.  These adverse events were comparable to the previous trials: most AEs were mild or moderate in severity and resolved within 14 days.

There were three serious adverse events of corporal rupture (penile fracture) and three serious adverse events of hematomas related to XIAFLEX reported in IMPRESS I and II.  All three corporal ruptures resolved following intervention and two of three hematomas resolved with intervention, with the third hematoma resolving without intervention.

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.27 -0.76%
FB $101.00 1.47%
GOOG $684.12 0.89%
TSLA $143.67 -3.09%
YHOO $27.10 1.04%


Chart of I:DJI
DOW 15,914.74 -99.64 -0.62%
S&P 500 1,851.86 -0.35 -0.02%
NASDAQ 4,283.5920 +14.8290 0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs